Amgen en las noticias
Desarrollo de terapias humanas innovadoras
Tamtam encontró 20 artículos recientes sobre Amgen.
- How Investors Are Reacting To Amgen (AMGN) Earnings Beat
- Amgen Inc. stock outperforms competitors on strong trading day
- Amgen announces Sjogren's trial results: Amgen stock gains 1.59 percent
- Amgen Inc Stock (AMGN) Moved Up by 3.06% on Oct 7: A Full Analysis
- Truist raises Amgen stock price target to $380 on pipeline growth
- Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Truist Financial Analyst Says
- Amgen (AMGN) Advances While Market Declines: Some Information for Investors
- Ada Visa Joins Amgen as Global Development Scientist Director
- Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
- 3,524 Amgen Inc. $AMGN Shares Sold by Colton Groome Financial Advisors LLC
- Amgen stock faces a USD 400 Cantor Fitzgerald target
- 2,546 Amgen Inc. $AMGN Shares Sold by Argent Capital Management LLC
- Why is Amgen (NASDAQ:AMGN) stock in focus as its obesity pipeline advances?
- Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 By Investing.com
- Amgen (NASDAQ:AMGN) Stock Purchase Disclosed by Rep. David Taylor
- David J. Taylor Purchases Amgen and Home Depot Stocks, Sells Marathon Petroleum
- Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock
- The biotech process development associate in Amgen’s grad programme
- Amgen (NASDAQ:AMGN) Scores Late-Stage Immunology Win
- More Than Skin Deep: Understanding Discoid Lupus Erythematosus
Artículos recopilados por Tamtam y conservados cuando tratan sobre la empresa, del más reciente al más antiguo. Cada uno enlaza con su fuente.
¿Vendes a empresas como Amgen?
Tamtam encuentra las empresas que encajan con tu cliente ideal, investiga cada cuenta y te dice a quién contactar y cuándo.
Encontrar empresas similares